Features | Partner Sites | Information | LinkXpress
Sign In
RANDOX LABORATORIES
GLOBETECH PUBLISHING
FOCUS DIAGNOSTICS, INC.

New Diagnostic Tool: Identification of Cancer Cells by Deformability Cytometry

By Labmedica International staff writers
Posted on 09 Dec 2013
Image: An artist’s depiction of a cell being squeezed in a high-speed fluid flow (Photo courtesy of UCLA - University of California, Los Angeles).
Image: An artist’s depiction of a cell being squeezed in a high-speed fluid flow (Photo courtesy of UCLA - University of California, Los Angeles).
Image: Invasive deformability: a transition to invasive malignant cells in a tumor is associated with the cell\'s increased ability to stretch, which may allow for invasion through tight tissue junctions (Photo courtesy of UCLA - University of California, Los Angeles).
Image: Invasive deformability: a transition to invasive malignant cells in a tumor is associated with the cell\'s increased ability to stretch, which may allow for invasion through tight tissue junctions (Photo courtesy of UCLA - University of California, Los Angeles).
A system that classifies individual cells according to their structural behavior (mechanophenotyping) has been used to identify cancers in cases that were difficult or impossible to resolve with traditional cytological techniques.

Investigators at the University of California, Los Angeles (USA) based the development of the "deformability cytometer" on the understanding that cells are not simple sacks of fluid. They also contain viscous and elastic properties related to the membranes that surround them; their internal structural elements, such as organelles; and the packed DNA arrangement in their nuclei. Because variations in these properties can provide information about cells' state of activity and can be indicative of diseases such as cancer, they are important to measure.

The deformability cytometer instrument consists of a miniaturized microfluidic chip that sequentially aligns cells so that they hit a wall of fluid at rates of thousands of cells per second. A specialized camera captures microscopic images of these cells at intervals of 140,000 pictures per second, and these images are then automatically analyzed by custom software to extract information about the cells' physical properties.

In a study, the investigators at the University of California, Los Angeles and colleagues at Harvard University (Boston, MA, USA) used the technique to diagnose malignant pleural effusions, in which disseminated tumor cells are difficult to accurately identify by traditional cytology.

An algorithmic diagnostic scoring system was established on the basis of quantitative features of two-dimensional distributions of single-cell mechanophenotypes from 119 samples. The scoring system classified 63% of the samples into two high-confidence regimes with 100% positive predictive value or 100% negative predictive value, and achieved an area under the curve of 0.86. This performance was suitable for a prescreening role to focus cytopathologist analysis time on a smaller fraction of difficult samples. In addition, samples labeled as “atypical cells,” which require additional time and follow-up, were classified in high-confidence regimes in eight of 15 cases. Further, 10 of 17 cytology-negative samples corresponding to patients with concurrent cancer were correctly classified as malignant or negative, in agreement with six-month outcomes.

"Building off of these results, we are starting studies with many more patients to determine if this could be a cost-effective diagnostic tool and provide even more detailed information about cancer origin," said senior author Dr. Dino Di Carlo, associate professor of bioengineering at the University of California, Los Angeles. "It could help to reduce laboratory workload and accelerate diagnosis, as well as offer doctors a new way to improve clinical decision-making."

The clinical study was published in the November 20, 2013, online edition of the journal Science Translational Medicine.

Related Links:

University of California, Los Angeles
Harvard University



PURITAN MEDICAL
EUROIMMUN AG
Sekisui Diagnostics
comments powered by Disqus
Life Technologies

Channels

Clinical Chemistry

view channel
Image: Enzyme-linked immunosorbent kit (ELISA) specific for human copeptin (Photo courtesy of USCN Life Science).

Preeclampsia Biomarker Detected Very Early In Pregnancy

A biomarker has been discovered that could give expecting mothers and their doctors the first simple blood test to reliably predict that a pregnant woman may develop preeclampsia, at least as early as... Read more

Pathology

view channel
Image: Glioblastoma multiforme (GBM) (Photo courtesy of the University of California, San Diego School of Medicine).

Brain Tumor Chemotherapy Biomarkers Identified

Cancer researchers have identified a new biomarker that they believe can predict whether glioblastoma multiformes (GBMs), the most common and aggressive type of malignant brain tumor, will be susceptible... Read more

Industry News

view channel

Beckman Coulter Acquires Siemens Healthcare Diagnostics’ Clinical Microbiology Business

Beckman Coulter (Brea, CA, USA), an indirect wholly-owned subsidiary of Danaher Corp. (Washington DC, MD, USA) has entered into a definitive agreement to purchase the clinical microbiology business of Siemens Healthcare Diagnostics (Chicago, IL, USA). The transaction is expected to close in the first quarter of 2015.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.